Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
An outer membrane vesicle vaccine against acute, systemic disease caused by meningococci of serogroup B has been developed. The vaccine has been tested consecutively in phase I and phase II clinical trials including more than 5000 volunteers. These trials provided data on safety, immunogenicity and reactogenicity and possible effect on carriage of meningococci in the throat, and consequently formed the basis for two major protection trials; one in secondary school students and one among military recruits. The aims, design and major results of phase I and phase II studies are described as well as the design and organization of the protection trials.
Bjune
G
G
National Institute of Public Health, Oslo.
Closs
O
O
Frøholm
L O
LO
Grønnesby
J K
JK
Høiby
E A
EA
Nøkleby
H
H
D000293:Adolescent; D000328:Adult; D016667:Bacterial Capsules; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology / Q000592:standards*; D004341:Drug Evaluation / Q000592:standards*; D005260:Female; D006801:Humans; D008297:Male; D022401:Meningococcal Vaccines; D008889:Military Personnel; D009664:Norway; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012107:Research Design / Q000592:standards*; D012703:Serotyping; D013334:Students
D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; C039455:capsular polysaccharide, meningococcal group B